MFDS approves new ‘Olumiant Tab,’ rheumatoid arthritis treatment

Published: 2017-12-13 16:27:00
Updated: 2017-12-13 14:01:15

The Ministry of Food and Drug Safety announced the ministry approved the Lilly Korea’s 2 products including ‘Olumiant Tab 2mg(generic name: baricitinib)’ and ‘Olumiant Tab 4mg(generic name: baricitinib)’ as a rheumatoid arthritis treatment on 11 December.

‘Olumiant Tab,’ an selective and reversi...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean




Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.